Figure 3.

Anti-tumour response of surv.VLP-SS-MUC1 in therapeutic tumour trial. (a) Expression of MUC1 and PD-L1 (following IFN-y stimulation) by C57mg.MUC1 cells. (b) Timeline of tumour trial. C57/BL6 mice (n = 10 mice per treatment group) were inoculated with C57mg.MUC1 tumour cells in the mammary fat pad (MFP). Once tumours were palpable (day 7), mice were vaccinated with VLPs delivering one or two antigens or controls. Tumour growth (c) and overall survival (d) for each treatment group were recorded. Once tumour size reached 150 mm² mice were euthanised and tumours analysed for TILs by flow cytometry (e) and IHC for CD3 (f). Statistical significance was determined by a log-rank (Mantel–Cox) test for survival and Mann–Whitney tests for TIL phenotype and IHC. *** p < 0.001, ** p < 0.01, * p < 0.05.